These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38558625)

  • 21. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.
    Gyldenløve M; Alinaghi F; Zachariae C; Skov L; Egeberg A
    Am J Clin Dermatol; 2022 Sep; 23(5):605-613. PubMed ID: 35737251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
    Gao JC; Wu AG; Contento MN; Maher JM; Cline A
    Clin Cosmet Investig Dermatol; 2022; 15():395-402. PubMed ID: 35300435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
    Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in prescriptions of oral medications for psoriasis: A single-center retrospective study.
    Takano-Kawasaki S; Sato E; Yamaguchi K; Imafuku S
    J Dermatol; 2023 Jan; 50(1):82-88. PubMed ID: 36229921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 34. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
    Distel J; Cazzaniga S; Seyed Jafari SM; Emelianov V; Schlapbach C; Yawalkar N; Heidemeyer K
    Dermatology; 2022; 238(2):267-275. PubMed ID: 34091455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 39. Recurrence of Melanoma after Starting Apremilast for Psoriasis.
    Salopek TG
    Case Rep Dermatol; 2017; 9(2):108-111. PubMed ID: 29033813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
    Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
    J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.